Prostate Cancer Studies
This study tests an estradiol cream for testosterone suppression in men with advanced androgen-sensitive prostate cancer.
This is a dermal administration (versus oral in other medications). Eligible patients may receive medication or placebo.
Men who are starting or restarting Lupron. Patients who have been on testosterone suppression therapy for at least 2 months but no more than 3 years.
This study compares the cardiovascular effects of two testosterone suppression medications for prostate cancer.
Eligible patients are randomly assigned to one medicine or the other, then are in study for 1 year.
Men who are going to start hormone therapy for the first time and have had a cardiovascular event within the past 5 years.
This is a Registry for patients who have Castrate Resistant Prostate Cancer.
Castrate Resistant Prostate Cancer (CRPC)
Registry for eligible, castrate-resistant patients. Interview by phone on quarterly basis.
Patients who have CRPC or hormone refractory prostate cancer or evidence of metastatic disease and are starting any advanced prostate cancer intervention.